Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
01 Jun 2019
Historique:
received: 18 11 2018
revised: 14 03 2019
accepted: 15 03 2019
pubmed: 30 3 2019
medline: 29 5 2019
entrez: 30 3 2019
Statut: ppublish

Résumé

In general, potent non-ketolide versions of erythromycin possessed conformationally constricted two- or three-atom-length sidechains at 3-OH. Novel 14-membered non-ketolides possessing long spacers beyond three-atom length were evaluated for antibacterial activity. The most potent one is 34a, featuring a five-atom-length flexible linker from of a pyridine ring to the aglycone. Conversion of the pyridine of 34a to other aryl groups, changing the linker's length of 34a to longer or shorter ones, and variation of the linker flexibility to a rigid olefin or alkyne led to decreased antibacterial activity. The hybrids of macrolides and quinolones 28b, 31 and 34b possessing various sidechains, unlike their 15-membered counterparts, were ineffective compared to 34a. Similar to the marketed ketolide telithromycin, the non-ketolide 34a proved to be a time-dependent bactericidal agent, but it exhibited superior in vivo pharmacokinetic properties such as longer half-life, higher plasma concentration, lower clearance and shorter time to reach the highest drug concentration relative to telithromycin. Molecular docking suggested 34a might π - π interact with the bacterial ribosomal RNA base G2505Ec. This study suggested that the bacteriostatic agent erythromycin can be structurally modified to afford a new bactericidal chemotype that targets the ribosome and is superior to ciprofloxacin with regard to its minimum bactericidal concentration.

Identifiants

pubmed: 30925339
pii: S0223-5234(19)30255-7
doi: 10.1016/j.ejmech.2019.03.037
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Clarithromycin H1250JIK0A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-254

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Xue-Meng Li (XM)

School of Life Science, Beijing Institute of Technology, Beijing 100081, China.

Wei Lv (W)

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, The Purdue Center for Cancer Research, Purdue University 47907, USA.

Si-Yang Guo (SY)

School of Life Science, Beijing Institute of Technology, Beijing 100081, China.

Ya-Xin Li (YX)

School of Life Science, Beijing Institute of Technology, Beijing 100081, China.

Bing-Zhi Fan (BZ)

School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China.

Mark Cushman (M)

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, The Purdue Center for Cancer Research, Purdue University 47907, USA.

Fan-Sheng Kong (FS)

Beijing Increasepharm Safety & Efficacy Co. Ltd, Beijing 102206, China.

Jun Zhang (J)

School of Life Science, Beijing Institute of Technology, Beijing 100081, China.

Jian-Hua Liang (JH)

School of Life Science, Beijing Institute of Technology, Beijing 100081, China; School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China. Electronic address: ljhbit@bit.edu.cn.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Animals Hemiptera Insect Proteins Phylogeny Insecticides
Populus Soil Microbiology Soil Microbiota Fungi

Classifications MeSH